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Pretreatment With Intracoronary Enalaprilat Protects
Human Myocardium During Percutaneous Coronary Angioplasty
Massoud A. Leesar, MD, Hani Jneid, MD, Xian-Liang Tang, MD, Roberto Bolli, MD
Louisville, Kentucky
Objectives We tested the hypothesis that enalaprilat induces preconditioning (PC)-mimetic actions in patients with stable
coronary artery disease.
Background Angiotensin-converting enzyme (ACE) inhibitors increase the bioavailability of bradykinin, which induces cardiac PC.
Methods Twenty-two patients undergoing coronary angioplasty were randomized to an intracoronary infusion of enalapri-
lat or placebo, followed 10 min later by a PC protocol.
Results In control patients, the ST-segment shift was greater during the first inflation than during the second and third
inflations, both on the intracoronary electrocardiogram (ECG) (21.0  2.8 mm vs. 13.0  2.0 mm and 13.0 
2.0 mm, p  0.05) and the surface ECG (16.0  4.0 mm vs. 10.0  2.0 mm and 9.0  2.0 mm, p  0.05).
In contrast, enalaprilat-pretreated patients showed no change in ST-segment shift during inflations on either the
intracoronary or the surface ECG. During the first inflation, the ST-segment shift was significantly smaller in
treated versus control patients. The chest pain score during the first inflation was also significantly smaller in
treated patients versus control patients (33.0  6.0 mm vs. 64.0  6.0 mm) and did not change in treated pa-
tients during the second and third inflations, whereas it decreased significantly in control patients. In a subset of
6 patients, enalaprilat increased coronary blood flow during infusion, but this effect dissipated before the begin-
ning of angioplasty.
Conclusions Pretreatment with enalaprilat attenuates the manifestations of myocardial ischemia during angioplasty. This is
the first in vivo evidence showing that an ACE inhibitor protects human myocardium, possibly via PC-mimetics
actions, a novel property that might explain the cardioprotective actions of these drugs. (J Am Coll Cardiol
2007;49:1607–10) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.060a
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lnhibitors of the angiotensin-converting enzyme (ACE)
ave been shown to exert beneficial actions in patients with
schemic heart disease (1). In particular, several studies have
ocumented a reduction in the occurrence of myocardial
nfarction and ischemic events among patients receiving
hese drugs (1,2). Although the mechanism responsible for
hese salubrious actions remains unclear, inhibition of bra-
ykinin degradation (which is catalyzed by the ACE) has
een proposed as a plausible mechanism (3).
Because ACE inhibitors potentiate bradykinin, which
nduces cardiac preconditioning (PC), one would expect
hat these drugs would elicit a PC-mimetic state. However,
hus far, no evidence has been reported to suggest that ACE
nhibitors are capable of inducing PC in humans. The goal
f this study was to determine whether enalaprilat, the
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tudy was supported in part by National Institutes of Health grants HL-55757,
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006, accepted January 1, 2007.ctive metabolite of enalapril, exerts PC-mimetic actions in
he human heart.
ethods
e enrolled 22 patients with chronic stable angina and
reserved left ventricular function who were referred for
lective angioplasty of an isolated coronary obstructive
esion. Criteria for inclusion and exclusion have been de-
ailed previously (4). Patients on oral ACE inhibitors were
xcluded from this study.
The protocols for drug infusion, angioplasty, and data
ollection have been previously reported (4). Patients were
ssigned to receive intracoronary enalaprilat or normal saline
efore percutaneous transluminal coronary angioplasty
PTCA). Enalaprilat (Merck, North Wales, Pennsylvania;
.75 mg in 50 ml saline) was infused over 15 min at 0.05
g/min directly into the stenotic artery (total dose 0.75 mg).
he placebo group received an equivalent volume of saline.
he intracoronary electrocardiogram (ECG) and surface ECG
eads were recorded, as previously reported (5). Coronary blood
ow (CBF) measurements were performed in a subset of 6
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Enalaprilat and Preconditioning April 17, 2007:1607–10enalaprilat-treated patients using
a 0.014-inch Doppler guidewire
(4). The study was approved by
the institutional review board.
All data are reported as mean
SEM. The ST-segment shift,
chest pain score, coronary flow,
and vessel diameter were ana-
lyzed with a 2-way repeated-
measures analysis of variance for
time and treatment. Post hoc
contrasts between groups at var-
ous time points or between time points within 1 group were
erformed with a 2-tailed Student t test using the Bonfer-
oni correction. Other continuous or dichotomous variables
ere compared between the 2 groups using Student t tests
r chi-square tests, respectively.
esults
he baseline and demographic characteristics of the patients
re summarized in Table 1. Enalaprilat administration did
ot produce appreciable changes in heart rate (73  4
eats/min vs. 71  3 beats/min in control patients), arterial
lood pressure (127  6 mm Hg vs. 131  8 mm Hg) or
ate-pressure product (9.8  103  0.8  103 vs. 9.3  103
0.8  103).
lectrocardiographic signs of ischemia. In the placebo
roup, the ST-segment shift was significantly greater during
he first balloon inflation than during the second and third
nflations, both on the intracoronary ECG (21.0  2.8 mm
s. 13.0  2.0 mm and 13.0  2.0 mm, respectively, p 
.05) and on the surface ECG (16.0  4.0 mm vs. 10.0 
.0 mm and 9.0  2.0 mm, respectively, p  0.05) (Fig. 1).
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
CBF  coronary blood flow
ECG  electrocardiogram
PC  preconditioning
PTCA  percutaneous
transluminal coronary
angioplasty
emographic and Clinicalharacteristics of the P tients
Table 1 Demographic and ClinicalCharacteristics of the Patients
Placebo
(n  11)
Enalaprilat
(n  11)
Age (yrs) 50 3 54 3
Gender, M/F 7/4 9/2
Hypertension 9 8
Smoking 5 8
Diabetes mellitus 4 3
Previous CABG 0 0
Previous PTCA 0 1
Left ventricular ejection fraction (%) 58 1 54 2
CCS anginal syndrome on admission
1–2 7 6
3–4 4 5
Interval between most recent angina
and PTCA (days)
3.8 1.1 4.0 1.2
Antianginal medications
Long-acting nitrates 11 10
Calcium channel blocking agents 1 0
Beta-blocking agents 10 11i
ABG  coronary artery bypass graft; CCS  Canadian Cardiovascular Society; PTCA  percuta-
eous transluminal coronary angioplasty.n contrast, the enalaprilat-pretreated group showed no
hange in the ST-segment shift during any of the 3 balloon
nflations on either the intracoronary ECG (10.0 2.0 mm
s. 10 2.0 mm and 9.0 2.0 mm, p NS) or the surface
CG (8.0  2.0 mm vs. 8.0  2.0 mm and 8.0  2.0 mm,
 NS) (Fig. 1). The ST-segment shift recorded on the
ntracoronary ECG was significantly smaller in the
nalaprilat-pretreated group compared with the placebo
roup during the first balloon inflation (10.0  2.0 mm vs.
1.0  2.8 mm, 11 mm, p  0.05), but did not differ
ignificantly between groups during the second and third
nflations (13.0  2.0 mm vs. 10.0  2.0 mm and 13.0 
.0 mm vs. 9.0  2.0 mm in control and treated patients,
espectively, p  NS) (Fig. 1). Similarly, the ST-segment
hift recorded on the surface ECG was significantly smaller
Figure 1 ST-Segment Shifts and Chest Pain Score
in Control Versus EN-Treated Patients
ST-segment shift on the intracoronary electrocardiogram (ECG) (top) and sur-
face ECG (middle) and chest pain score (bottom) in patients pretreated with
either normal saline (control) or enalaprilat (EN).n the enalaprilat group compared with placebo during the
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April 17, 2007:1607–10 Enalaprilat and Preconditioningrst balloon inflation (8.0  2.0 mm vs. 16.0  4.0 mm,
 0.05), but not during the second and third inflations
10.0  2.0 mm vs. 8.0  2.0 mm and 9.0  2.0 mm vs. 10
s. 8.0  2.0 mm in control and treated patients, respec-
ively, p  NS) (Fig. 1).
hest pain. The chest pain score in the placebo group was
ignificantly greater during the first than during the second
nd third balloon inflations (64.0  6.0 mm vs. 49.0  8.0
m and 40.0  8.0 mm, p  0.05) (Fig. 1). In contrast, in
he enalaprilat-pretreated group the chest pain score did not
iffer significantly among inflations (33.0  6.0 mm vs.
4.0  7.0 mm and 34.0  6.0 mm, p  NS). The chest
ain score was significantly smaller in the enalaprilat group
ompared with control patients during the first (33.0  6.0
m vs. 64.0  6.0 mm, p  0.05) and second (34.0  7.0
m vs. 49.0  8.0 mm, p  0.05) balloon inflations, but
ot during the third balloon inflation (34.0  6.0 mm vs.
0.0  8.0 mm, p  NS).
BF. The average CBF increased significantly during enal-
prilat infusion (77.8  10.3 ml/min vs. 188.8  31.0
l/min, p  0.006) but returned to baseline levels shortly
fter the end of the infusion (within 10 min) (80.2  8.9
l/min, p  0.8) (Fig. 2). Enalaprilat did not produce
picardial coronary vasodilation, because no significant
hanges in minimal coronary luminal diameter were ob-
erved before, during, or after the intracoronary infusion
3.06  0.11 mm vs. 3.25  0.12 mm vs. 3.14  0.12 mm,
 NS) (Fig. 3).
iscussion
he results of this study show that pretreatment with
nalaprilat results in less ST-segment shift and less chest
ain during the first balloon inflation in patients undergoing
lective PTCA. Although in control patients, the electro-
Figure 2 Measurements of Coronary Blood Flow
Measurements were taken at baseline, at the end
of the infusion of enalaprilat (EN), and 10 min after EN.tardiographic and subjective manifestations of ischemia
ere attenuated during the second and third balloon inflations
ompared with the first (a manifestation of ischemic PC), in
nalaprilat-pretreated patients there was virtually no change
n any of these parameters, indicating that the superimpo-
ition of ischemic PC to enalaprilat pretreatment did not
rovide additional protection beyond that provided by the
rug (i.e., the myocardium was maximally protected by
nalaprilat). The augmented tolerance to ischemia conferred
y enalaprilat was observed after the CBF returned to
aseline and was not influenced by concomitant medical
herapy.
Although we did not measure blood enalaprilat levels, it
eems plausible that the protection afforded by enalaprilat
epresents a form of pharmacological PC rather than a
irect anti-ischemic effect of the drug, because such an effect
as observed 10 min after the end of the infusion, when the
oronary vasodilatory effects of the drug had completely
esolved. If biologically active levels of enalaprilat were still
resent during balloon inflation, one would have expected
he coronary vasodilation to persist. The mechanism
hereby enalaprilat induces PC may involve potentiation of
radykinin, which is known to precondition myocardium
xperimentally (5) and to induce PC in the setting of PTCA
4). Theoretically, it is also possible that the protective effect
f enalaprilat may have been triggered by the transient
ncrease in CBF, possibly via endothelial shear-mediated
echanisms. However, ACE inhibitors potentiate PC in
solated human cardiac tissue (6), suggesting that the PC
ffect of enalaprilat is independent of coronary flow changes.
Previous studies have shown the ability of ACE inhibi-
ors to alleviate experimental myocardial ischemia/
eperfusion injury (5) and to extend the duration (but not
Figure 3 Minimal Lumen Diameter Before EN,
at the End of the Infusion, and 10 Min Later
EN  enalaprilat.he magnitude) of the “warm up” phenomenon in patients
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Enalaprilat and Preconditioning April 17, 2007:1607–10ndergoing exercise tolerance tests (7). However, to our
nowledge, this is the first in vivo evidence that ACE
nhibitors protect human myocardium against ischemia.
An inevitable limitation of studies of PTCA is that in
ontrast to animal experiments in which infarct size has
een used as the end point to assess the role of bradykinin
r ACE inhibitors in PC (8), in the present study the main
nd point was the magnitude of the ST-segment shift. The
T-segment elevation is a surrogate marker of ischemia, and
s such its reliability has been questioned (9). However, the
ttenuation of ST-segment elevation during PTCA is con-
ordant (in both direction and magnitude) with changes in
ther parameters of ischemia (lactate production, H re-
ease, echocardiographic measurements of systolic and dia-
tolic function), suggesting that ST-segment shifts are a
seful marker of the severity of ischemia in humans (10).
imilar conclusions have been reached in experimental
odels (reviewed by Leesar et al. [10]).
Our results are consistent with numerous experimental
tudies that have documented cardioprotective effects of
arious ACE inhibitors in animal models (11,12). In addi-
ion, we (4) have shown that pretreatment with bradykinin
lleviates ischemia in the same clinical setting (PTCA) used
n the present study. Both adenosine and bradykinin (whose
ioavailability is enhanced by ACE inhibitors) can trigger
C experimentally (13), and ACE inhibitors potentiate
schemic PC in human atrial trabeculae through activation
f bradykinin receptors (6).
Our infusion rate of enalaprilat was based on previous
tudies (14). We were concerned that higher doses could
ave induced hypotension and/or ischemia, which in turn
ay have triggered PC and confounded the analysis.
In conclusion, this study reveals a novel action of ACE
nhibitors in humans that, if confirmed in larger trials, may
ave broad implications for the treatment of coronary artery
isease. The demonstration of the cardioprotective proper-
ies of enalaprilat in PTCA provides a mechanism for
xplaining the anti-ischemic actions of ACE inhibitors in
atients with coronary artery disease. The present results
arrant further investigation to determine whether ACE
nhibitors precondition the myocardium in settings associ-
ted with more severe ischemia (e.g., cardiac surgery, acuteyocardial infarction) and whether these actions translate
nto tangible benefits.
eprint requests and correspondence: Dr. Roberto Bolli, Divi-
ion of Cardiology, University of Louisville, Louisville, Kentucky
0292. E-mail: rbolli@louisville.edu.
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